Literature DB >> 7224382

Phenytoin-induced methadone withdrawal.

T G Tong, S M Pond, M J Kreek, N F Jaffery, N L Benowitz.   

Abstract

Methadone-maintained volunteers experienced moderately severe opiate withdrawal symptoms within 3 or 4 days of beginning phenytoin in therapeutic doses. The area under the methadone plasma concentration-time curve decreased while the ratio of the pyrrolidine-to-metabolite excretion in urine to this area increased significantly. This suggests that phenytoin accelerates methadone metabolism. Methadone dosing adjustments should be anticipated when phenytoin is initiated or discontinued in methadone-maintained patients.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7224382     DOI: 10.7326/0003-4819-94-3-349

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  14 in total

1.  Use of methadone.

Authors:  I B Anderson; T E Kearney
Journal:  West J Med       Date:  2000-01

2.  [Not Available].

Authors:  J Jage
Journal:  Schmerz       Date:  1989-09       Impact factor: 1.107

Review 3.  Pharmacokinetic drug interactions with phenytoin (Part II).

Authors:  R L Nation; A M Evans; R W Milne
Journal:  Clin Pharmacokinet       Date:  1990-02       Impact factor: 6.447

Review 4.  Pharmacokinetic and pharmacodynamic principles of illicit drug use and treatment of illicit drug users.

Authors:  D I Quinn; A Wodak; R O Day
Journal:  Clin Pharmacokinet       Date:  1997-11       Impact factor: 6.447

Review 5.  Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence.

Authors:  Chin B Eap; Thierry Buclin; Pierre Baumann
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

6.  Steady-state pharmacokinetics of methadone in opioid addicts.

Authors:  K Wolff; A W Hay; D Raistrick; R Calvert
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

7.  The pharmacokinetics of methadone in HIV-positive patients receiving the non-nucleoside reverse transcriptase inhibitor efavirenz.

Authors:  S M Clarke; F M Mulcahy; J Tjia; H E Reynolds; S E Gibbons; M G Barry; D J Back
Journal:  Br J Clin Pharmacol       Date:  2001-03       Impact factor: 4.335

Review 8.  Interindividual variability of methadone response: impact of genetic polymorphism.

Authors:  Yongfang Li; Jean-Pierre Kantelip; Pauline Gerritsen-van Schieveen; Siamak Davani
Journal:  Mol Diagn Ther       Date:  2008       Impact factor: 4.074

9.  ABCB1 (MDR1) genetic variants are associated with methadone doses required for effective treatment of heroin dependence.

Authors:  Orna Levran; Kimberly O'Hara; Einat Peles; Dawei Li; Sandra Barral; Brenda Ray; Lisa Borg; Jurg Ott; Miriam Adelson; Mary Jeanne Kreek
Journal:  Hum Mol Genet       Date:  2008-04-17       Impact factor: 6.150

Review 10.  Drug interactions of clinical significance with opioid analgesics.

Authors:  P M Maurer; R R Bartkowski
Journal:  Drug Saf       Date:  1993-01       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.